Literature DB >> 26308187

Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.

Giovanni Caocci1, Antonio Maccioni2, Francesca Murgia1, Alessandra Perra1, Monica Usai1, Michela Piga2, Roberto Mascia2, Giorgio La Nasa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26308187     DOI： 10.3109/10428194.2015.1079320

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  Christina Hart; Sabine Klatt; Johann Barop; Gunnar Müller; Roland Schelker; Ernst Holler; Elisabeth Huber; Wolfgang Herr; Jochen Grassinger
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

2.  Ruxolitinib therapy and telomere length in myelofibrosis.

Authors:  G Caocci; M Greco; G Delogu; C Secchi; A Perra; S Ghiani; F Orru; A Vacca; F Galimi; G La Nasa
Journal:  Blood Cancer J       Date:  2016-10-07       Impact factor: 11.037
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.